ArticleLeukemia & lymphoma2016

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Viralkumar Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.